



The 65th ASH Annual Meeting Abstracts

ORAL ABSTRACTS

616.ACUTE MYELOID LEUKEMIAS: INVESTIGATIONAL THERAPIES, EXCLUDING TRANSPLANTATION AND CELLULAR IMMUNOTHERAPIES**Early Results of the Phase I/II Study Investigating the All-Oral Combination of the Menin Inhibitor Revumenib (SNDX-5613) with Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE)**

Ghayas C. Issa, MD¹, Branko Cuglievan, MD², Courtney D. DiNardo, MD MSc¹, Nicholas J. Short, MD¹, David McCall, MD³, Amber Gibson, DO², Cesar Nunez, MD², Miriam B. Garcia, DO², Michael Roth, MD⁴, Aram Bidikian, MD¹, Allison Pike, RN¹, Sheila Tan, RN¹, Brianna Kammerer, BSN,MS,RN⁴, Musa Yilmaz, MD¹, Tapan M. Kadia, MD¹, Naveen Pemmaraju, MD¹, Maro Ohanian, DO¹, Naval Daver, MD¹, Elias Jabbour, MD⁵, Gautam Borthakur, MD¹, Farhad Ravandi, MD MBBS¹, Guillermo Garcia-Manero, MD⁶, Michael Andreeff, MD PhD⁷, Hagop M. Kantarjian, MD¹

¹Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

²Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX

³Division of Pediatrics, MD Anderson, Houston, TX

⁴Department of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX

⁵University of Texas M.D. Anderson Cancer Ctr., Houston, TX

⁶University of Texas MD Anderson Cancer Center, Houston, TX

⁷Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

Background: The interaction of menin with lysine methyltransferase 2A (KMT2A) is a dependency in acute leukemia caused by either rearrangement of the *KMT2A* (*KMT2Ar*) or *Nucleoporin 98* (*NUP98r*) genes, or mutation of the *Nucleophosmin 1* gene (*NPM1mt*). The menin inhibitor revumenib (previously SNDX-5613), is a potent, oral, selective inhibitor of the menin-KMT2A interaction with demonstrated safety and clinical activity in highly refractory acute leukemias (Issa GC, Nature 2023). *KMT2Ar* or *NPM1mt* leukemias are highly susceptible to induction of apoptosis through BCL2 inhibition, and dual Bcl-2 and menin inhibition led to synergistic activity in *KMT2Ar* or *NPM1mt* leukemia models (Carter BZ, Blood 2021). Therefore, we designed a phase I/II, investigator-initiated trial of the all-oral combination of revumenib, venetoclax and the hypomethylating agent ASTX727 in children and adults with relapsed/refractory (R/R) acute myeloid leukemia (AML) (NCT05360160).

Methods: Patients (pts) with R/R AML or myeloid mixed-lineage acute leukemia (MPAL) aged 12 years and older were eligible. Dose escalation followed a 3+3 design. ASTX727 (decitabine/ cedazuridine) was administered at 35 mg/100 mg PO daily days 1-5, venetoclax at 400 mg (target dose) PO daily days 1-14, and revumenib 113 mg PO Q12h (dose level [DL] 0) or 163 mg PO Q12h (DL 1, used in phase II monotherapy), days 1-28 with either posaconazole or voriconazole (strong CYP3A4 inhibitors, for antifungal prophylaxis). Maintenance with revumenib monotherapy is planned following hematopoietic stem cell transplant (HSCT) for 1 year. For the first pt cohort, bone marrow examination was performed on cycle 1 day 14 and at the end of the cycle to assess for early morphologic remission and to inform future dose adjustments.

Results: As of 7/20/2023, 8 pts were enrolled, 6 at DL0, and 2 at DL1. The median age was 27 years (range, 12-62 years), including 2 children (ages 12 and 16), 5 with *KMT2Ar*, 2 with *NUP98r* and 1 with *NPM1mt*. One pt had MPAL, and one had bone marrow and extramedullary disease. The median prior lines of therapy was 2.5 (range 1-4), 5 pts (63%) had prior venetoclax, 5 pts (63%) had a prior hypomethylating agent, 5 pts (63%) had prior HSCT, and one had prior menin inhibitor. The most common all-grade treatment-related adverse events (TRAEs) in ≥25% of pts were febrile neutropenia (63%), hyperphosphatemia (63%), nausea (63%), and AST/ALT elevation (25%). Grade ≥ 3 TRAEs were febrile neutropenia (63%), decreased platelets count (25%), and decreased neutrophil count (25%). There was 1 dose-limiting toxicity (DLT), grade 4 prolonged thrombocytopenia and neutropenia, at DL0 (resolved after dose hold), prompting enrollment of 3 additional pts, and escalation to DL1 when no additional DLTs were noted (1/6 pts with DLT). Pts at DL1 (N=2) have not completed the DLT period. There were no deaths due to TRAEs. No grade 3 or higher QTc prolongation occurred. Two pts had grade 2 differentiation syndrome (bone pain only), resolved with steroids. One pt (*NUP98r*) had asymptomatic leukocytosis at the end of cycle 1 with neutrophilia, monocytosis, decrease in peripheral blasts, decrease in bone marrow blasts from 66% to 8%, and persistence of *NUP98r* by fluorescence in situ hybridization at 90% indicating differentiation.

Seven of 8 pts are response-evaluable, and all 7 attained a morphologic remission (overall response rate of 100%) (Figure 1). Best responses achieved included a complete remission (CR) in 1 pt (including resolution of extramedullary disease), CR with partial hematologic recovery (CRh) in 1 pt, CR with incomplete platelet count recovery (CRp) in 3 pts, partial response (PR) in 1 pt, and 1 pt with morphologic leukemia free state (MLFS). Measurable residual disease was undetectable by flow (sensitivity at 10^{-4}) in 3 of 7 pts (43%). Three pts transitioned to HSCT following response, 2 are in continued remission, 1 has started maintenance and 1 pt died of transplant complications prior to starting maintenance. Enrollment is ongoing and updated data will be presented.

Conclusions: Early results indicate acceptable safety and high efficacy of this combination in R/R myeloid leukemias with either KMT2Ar or NPM1mt or NUP98r. This study is ongoing with plans to establish the recommended phase 2 dose and optimize delivery of this combination.

Disclosures Issa: NuProbe: Consultancy; Syndax: Research Funding; Novartis: Consultancy, Research Funding; Celgene: Research Funding; Merck: Research Funding; Kura Oncology: Consultancy, Research Funding. **DiNardo:** Notable Labs: Honoraria; Fogham: Honoraria; BMS: Honoraria; AbbVie/Genentech: Honoraria; Schrödinger: Consultancy; Novartis: Honoraria; ImmuniOnc: Honoraria; Takeda: Honoraria; Servier: Honoraria; Astellas: Honoraria. **Short:** Astellas: Research Funding; Amgen: Honoraria; AstraZeneca: Consultancy; Pfizer: Consultancy; Takeda: Consultancy, Research Funding; Stemline therapeutics: Research Funding; Novartis: Consultancy. **Roth:** Pfizer: Research Funding. **Yilmaz:** Pfizer: Research Funding; Daiichi-Sankyo: Research Funding. **Kadia:** Janssen Research and Development: Research Funding; Jazz Pharmaceuticals, Pfizer, Pulmotect, Inc, Regeneron Pharmaceuticals, SELLAS Life Sciences Group: Research Funding; AbbVie, Amgen, Inc, Ascentage Pharma Group, Astellas Pharma Global Development, Astex, AstraZeneca, BMS, Celgene, Cellenkos Inc, Cyclacel, Delta-Fly Pharma, Inc, Genentech, Inc., Genfleet, Glycomimetics, Iterion, Janssen Research and Development: Research Funding; Amgen, Inc.: Research Funding; Iterion: Research Funding; Astellas Pharma Global Development: Research Funding; Ascentage Pharma Group: Research Funding; SELLAS Life Sciences Group: Research Funding; Hikma Pharmaceuticals: Speakers Bureau; Regeneron Pharmaceuticals: Research Funding; Celgene: Research Funding; Cellenkos Inc.: Research Funding; Pfizer: Consultancy, Research Funding; Novartis: Consultancy; Liberum: Consultancy; Pulmotect, Inc.: Consultancy, Research Funding; Sanofi-Aventis: Consultancy; Biologix, Cure, Hikma Pharmaceuticals: Speakers Bureau; Genzyme: Honoraria; GenFleet Therapeutics: Research Funding; Cyclacel: Research Funding; Cure: Speakers Bureau; Glycomimetics: Research Funding; AstraZeneca: Research Funding; Delta-Fly Pharma, Inc.: Research Funding; Genentech: Consultancy, Research Funding; Daiichi Sankyo, Genentech, Inc., Genzyme, Jazz Pharmaceuticals, Liberum, Novartis, Pfizer, PinotBio, Inc, Pulmotect, Inc, Sanofi-Aventis, Servier: Consultancy; Agios: Consultancy; Servier: Consultancy; Pinotb-Bio: Consultancy; BMS: Consultancy, Research Funding; Astex: Honoraria. **Pemmaraju:** Incyte: Consultancy, Membership on an entity's Board of Directors or advisory committees; ClearView Healthcare Partners: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Novartis Pharmaceuticals: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; ImmunoGen: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; CTI BioPharma: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Blueprint: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; CancerNet: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Cimeio Therapeutics AG: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Aplastic Anemia & MDS International Foundation: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; ASH Committee on Communications: Other: Leadership; PharmaEssentia: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Physician Education Resource (PER): Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; CareDx: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; ASCO Cancer.Net Editorial Board: Other: Leadership; BMS: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; National Institute of Health/National Cancer Institute (NIH/NCI): Research Funding; Dan's House of Hope: Membership on an entity's Board of Directors or advisory committees; Pacylex: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Neopharm: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; EUSA Pharma: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Curio Science: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; PeerView Institute for Medical Education: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Celgene: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Patient Power: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; OncLive: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Dava Oncology: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Menarini Group: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Harborside Press: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Protagonist Therapeutics, Inc.: Consultancy, Membership on an entity's Board of Directors or advisory committees; Stemline: Consultancy, Membership on an entity's Board of Directors or advisory committees; United States Department of Defense (DOD): Research Funding; Karger Publishers: Other: Licenses; Medscape: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Magdalen Medical Publishing: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Intellisphere: Consultancy, Membership on an entity's Board of Directors

or advisory committees, Speakers Bureau; *Imedex*: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; *Astellas*: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; *Aptitude Health*: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; *AbbVie*: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; *HemOnc Times/Oncology Times*: Other: Uncompensated; *Bristol Myers Squibb Pharmaceuticals*: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau. **Daver**: *Genentech*: Consultancy, Research Funding; *Syndax*: Consultancy; *Trovagene*: Research Funding; *FATE*: Research Funding; *Novimmune*: Research Funding; *AROG*: Consultancy; *Glycomimetics*: Research Funding; *Novartis*: Consultancy; *ImmunoGen*: Consultancy, Research Funding; *Jazz*: Consultancy; *Astellas*: Consultancy, Research Funding; *Hanmi*: Research Funding; *Trillium*: Consultancy, Research Funding; *Daiichi Sankyo*: Consultancy, Research Funding; *Pfizer*: Consultancy, Research Funding; *Gilead*: Consultancy, Research Funding; *AbbVie*: Consultancy, Research Funding; *Bristol-Myers Squibb*: Consultancy, Research Funding; *Amgen*: Consultancy, Research Funding; *Servier*: Consultancy, Research Funding; *Agios*: Consultancy; *Shattuck Labs*: Consultancy; *Celgene*: Consultancy; *Kite, a Gilead company*: Consultancy, Research Funding; *Kronos Bio*: Research Funding. **Jabbour**: *Pfizer*: Consultancy, Honoraria, Research Funding; *Bristol-Myers Squibb*: Consultancy, Honoraria, Research Funding; *AbbVie*: Consultancy, Honoraria, Research Funding; *Genentech*: Consultancy, Honoraria, Research Funding; *Takeda*: Consultancy, Honoraria, Research Funding; *Ascentage Pharma Group*: Consultancy, Honoraria, Research Funding; *Adaptive Biotech*: Consultancy, Honoraria, Research Funding; *Amgen*: Consultancy, Honoraria, Research Funding; *Hikma Pharmaceuticals*: Consultancy, Honoraria, Research Funding. **Borthakur**: *Pacylex*, *Novartis*, *Cytomx*, *Bio Ascend*:: Membership on an entity's Board of Directors or advisory committees; *Catamaran Bio*, *AbbVie*, *PPD Development*, *Protagonist Therapeutics*, *Janssen*: Consultancy; *Astex Pharmaceuticals*, *Ryvuu*, *PTC Therapeutics*: Research Funding. **Ravandi**: *Prelude*: Research Funding; *AbbVie*: Consultancy, Honoraria, Research Funding; *Syros*: Consultancy, Honoraria, Research Funding; *Amgen*: Honoraria, Research Funding; *Astellas*: Consultancy, Honoraria, Research Funding; *Xencor*: Research Funding; *Biomea fusion*: Honoraria, Research Funding; *Celgene/BMS*: Consultancy, Honoraria, Research Funding; *Astex/taiho*: Membership on an entity's Board of Directors or advisory committees, Research Funding. **Garcia-Manero**: *Bristol Myers Squibb*: Other: Medical writing support, Research Funding; *Genentech*: Research Funding; *AbbVie*: Research Funding. **Andreeff**: *Kintor Pharmaceutical*: Research Funding; *PMV*: Research Funding. **Kantarjian**: *Ascentage Pharma Group*: Honoraria; *Immunogen (Inst)*: Honoraria, Research Funding; *Ipsen*: Honoraria; *Jazz Pharmaceuticals (Inst)*: Honoraria, Research Funding; *KAHR Medical*: Honoraria; *Novartis*: Honoraria; *Pfizer*: Honoraria; *Precision Biosciences*: Honoraria; *Shenzhen Target Rx*: Honoraria; *Taiho Pharmaceutical*: Honoraria; *AbbVie (Inst)*: Research Funding; *Amgen (Inst)*: Research Funding; *Ascentage Pharma (Inst)*: Research Funding; *Bristol-Myers Squibb (Inst)*: Research Funding; *Novartis (Inst)*: Research Funding; *Daiichi-Sankyo (Inst)*: Honoraria, Research Funding; *AstraZeneca/MedImmune*: Honoraria; *Astellas Pharma*: Honoraria; *Amgen*: Honoraria; *AbbVie*: Consultancy, Honoraria.

<https://doi.org/10.1182/blood-2023-182337>




Figure 1: Characterization of remissions. Abbreviations: HSCT, hematopoietic stem cell transplant; HMA, hypomethylating agent; Ven, venetoclax; Menin-I, menin inhibitor

Figure 1